Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus

Autor: Jesper Waldenström, Johan Westin, Staffan Nilsson, Peer Brehm Christensen, Kristoffer Hellstrand, Kristine Mørch, Martti Färkkilä, Gunnar Norkrans, Nina Langeland, Martin Lagging
Přispěvatelé: Centre of Excellence in Complex Disease Genetics, HUS Abdominal Center, Department of Medicine, Gastroenterologian yksikkö, University of Helsinki, Helsinki University Hospital Area
Rok vydání: 2021
Předmět:
Male
CLEARANCE
medicine.medical_treatment
IL28B
Hepacivirus
medicine.disease_cause
IFN-LAMBDA-4
0302 clinical medicine
antibody
gender
steatosis
Receptor
ASSOCIATIONS
0303 health sciences
Gastroenterology
SINGLE-NUCLEOTIDE POLYMORPHISMS
GENETIC-VARIATION
Hepatitis C
viral load
3. Good health
Cytokine
Interferon-lambda 4
HCV
030211 gastroenterology & hepatology
Antibody
Viral load
Genotype
HCV RNA
Hepatitis C virus
Interferon-λ 4
Single-nucleotide polymorphism
Biology
Antiviral Agents
Polymorphism
Single Nucleotide
03 medical and health sciences
medicine
Animals
Humans
IFN-lambda 4
030304 developmental biology
RECEPTOR
Interleukins
Hepatitis C
Chronic
medicine.disease
Virology
In vitro
CYTOKINE
3121 General medicine
internal medicine and other clinical medicine
IFN-λ4
biology.protein
Interferons
Steatosis
RESPONSES
Zdroj: Scandinavian Journal of Gastroenterology
Waldenström, J, Hellstrand, K, Westin, J, Nilsson, S, Christensen, P, Färkkilä, M, Mørch, K, Langeland, N, Norkrans, G & Lagging, M 2021, ' Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus ', Scandinavian Journal of Gastroenterology, vol. 56, no. 7, pp. 849-854 . https://doi.org/10.1080/00365521.2021.1922750
ISSN: 1502-7708
0036-5521
DOI: 10.1080/00365521.2021.1922750
Popis: Objectives: Despite recombinant interferon-λ 4 (IFN-λ4) demonstrating anti-viral activity in vitro and the ancestral functional gene (IFNL4) being conserved in all other primates, there has been speculation that IFN-λ4 may be detrimental in humans. In light of recent rekindled interest in humoral immunity, this study aimed at evaluating the impact of baseline characteristics, including IFNL4, on antibody levels to hepatitis C virus (HCV). Materials and methods: Pretreatment sera from 279 well-characterized North European Caucasians with chronic HCV genotype 2 or 3 infection having undergone liver biopsy were analyzed regarding IFNL4 (rs12979860) and anti-HCV antibody levels using a commercially available assay. Results: Patients producing IFN-λ4 had higher signal to cut-off (S/CO) anti-HCV antibody ratios as compared with those lacking IFN-λ4 (IFNL4 rs12979860 CT/TT versus CC, ps = −0.14, p =.02) was noted. In multivariate analysis IFN-λ4, gender, steatosis and viral load remained independently associated. Conclusions: To our knowledge, this is the first report that demonstrates that the ability to produce IFN-λ4, in addition to male gender, absent/mild steatosis, and lower viral load, augments antibody levels against HCV. This indicates that IFN-λ4 may be associated with T helper cell 2 (Th2) immune skewing, which might have clinical implications beyond HCV infection. ClinicalTrials.gov Identifier: NCT00143000.
Databáze: OpenAIRE
Externí odkaz: